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Abstract 
SBRT is an emerging effective treatment for hepatocellular carcinoma (HCC) 
associated with acceptable rates of toxicity in appropriately selected patients. Despite 
often being reserved for patients unsuitable for other local treatments, prospective 
and retrospective studies have demonstrated excellent long-term control. SBRT may 
be used as a stand-alone treatment, or as an adjunct to other HCC therapies. Based 
on available data, SBRT appears to complement existing local liver therapies. 
Randomised and non-randomized comparative studies are required to better 
determine the optimal role of SBRT in HCC treatment. 
 
Introduction 
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the 
third most common cause of cancer death1. Following resection or transplant of early 
stage HCC, 5-year survival is around 50-70%2. Unfortunately, only about 30% of HCC 
patients are suitable, as a result of poor liver function, poor general condition and/or 
the locally advanced nature of HCC3. In patients unsuitable for transplant or resection 
with smaller tumours, ablative therapies such as radiofrequency ablation (RFA) may 
result in long term control, with 5-year survival rates over 60% for tumours <3 cm, in 
selected patients4. Larger HCC and lesions adjacent to major vessels are less well 
suited for RFA. For patients inappropriate for curative options, some may be 
candidates for hepatic arterial transarterial chemoembolization (TACE) or drug eluting 
beads (DEB). Conventional TACE improves survival from 11-27% to 24-63% at 2 
years5 and DEB may provide additional benefit6. Sorafenib is another treatment that 
improves survival from 33% to 44% at 1 year compared to placebo in patients with 
intact liver function7.   
 
Traditionally, radiotherapy was not considered appropriate for HCC as the whole liver 
radiation tolerance is lower than the doses required for HCC ablation8. In addition, 
HCC most often occurs on a background of liver disease, and there is a fine balance 
between adequate treatment of the HCC and avoidance of liver toxicity.  Modern 
radiotherapy and imaging, however, permit ablative doses to be delivered to HCC, 
without excessive dose to normal liver. HCC SBRT was first described in 1995 by 
Blomgren et al.9. Robust target delineation, highly conformal planning, online image 
guidance and methods to minimise respiratory motion are required for optimal 
delivery. Despite often being reserved for patients unsuitable for other treatments, 
and in whom poor outcomes are expected, studies of SBRT in HCC have 
demonstrated excellent long-term control. SBRT may be used as a stand-alone 
treatment for patients unsuitable for standard treatments, and there is interest in its 
use as an alternative or adjunct to other HCC therapies. Due in part to a lack of level 
1 evidence, SBRT is currently not considered as standard treatment in most HCC 
management guidelines10-12. This review examines clinical advancements in SBRT 
for HCC. 
 
Clinical evidence: Prospective data 
A number of early phase trials specifically examining SBRT for HCC have been 
reported, amounting to more than 250 patients and in excess of 350 HCC lesions13-17. 
Key prospective studies are summarised in Table 1 and discussed below. 
 
Mendez Romero et al published the first prospective trial in 200613. Eight HCC 
patients, with 11 liver lesions measuring up to 7cm, ineligible for other local 
treatments, were included. The prescription dose was based on lesion size and 
presence of cirrhosis. Local control and overall survival at one year were both 75%. 
Local failure was only observed at the lowest dose (25Gy in 5 fractions). 
There was one episode of high-grade toxicity in a patient with Child-Pugh (CP) B 
cirrhosis who developed fatal radiation-induced liver disease.  
 
Kang et al, in 2012, published outcomes of a phase II trial of SBRT for HCC including 
47 patients with incomplete responses to TACE and mainly CP A disease14. The 2-
year local control and overall survival rates following SBRT (42-60Gy in 3 fractions) 
were 95% and 69% respectively. Grade 3+ toxicity included grade 3 
hyperbilirubinaemia (4%), ascites (4%) and thrombocytopaenia (11%) and grade 3/4 
gastrointestinal (GI) ulceration (11%). Progression from CP A to CP B disease 
occurred in 13% of patients.  
 
The largest prospective data series was published by Bujold et al in 201315. This 
phase I/II study included 102 patients, all CP A and unsuitable for other local liver 
therapy, most often with locally advanced HCC (55% with major portal vein invasion) 
and 12% had extra-hepatic disease.  Local control and overall survival at one year 
following 24-54Gy in 6 fractions were 87% and 55% respectively. Grade 3+ toxicity 
occurred in 30%, with 7 deaths occurring 1.1-7.7 months after SBRT, all considered 
possibly related to treatment (liver failure in 5, 2 with progressive HCC in the portal 
vein, cholangitis in 1, and upper GI bleed in 1). In addition, 29% of patients 
experienced a decline in CP class at 3 months.  
 
The above group also published outcomes for a combination of 29 prospective 
(n=14), and retrospective (n=15) patients with CP B and CP C disease, 76% with 
HCC portal vein thrombosis and 76% with extra hepatic disease18. The median 
prescribed dose was 30Gy in 6 fractions. Overall survival was 32% at 1 year, and 
was better in patients with CP B7 scores compared to higher, and in patients with 
AFP levels QJPO7KHUDWHRISURJUHVsion at 12 months was 45%. A decline in 
CP score of 2 were observed in 63% at 3 months. 
 
More recently, Lasely et al, in 2015, reported Phase I/II trial results for 38 CP A and 
21 CP B patients with 65 lesions16. Up to three lesions with a combined diameter of 
FPand 0.5cm away from bowel or stomach wall were eligible. Patients had to be 
ineligible for resection or transplant, although not necessarily ineligible for other 
therapies. Prescription doses were initially 36-48Gy in 3 fractions. After the 
observation of increased toxicity in CP B7+ patients, the dose for CP B patients was 
changed to 40Gy in 5 fractions and CP B8+ patients were excluded from the trial. 
Local control at 1 and 3 years was 91% in CP A patients, and 82% in CP B. Grade 
3/4 liver toxicity was observed in 11% of CP A patients, and 38% of CP B. For CP B 
patients, those who experienced grade 3+ toxicity had higher mean liver doses, 
higher doses to 1/3 of the normal liver and larger volumes of liver receiving up to 
15Gy.  
 
Also in 2015, Scorsetti et al published outcomes for 23 CP A and 20 CP B patients 
with 63 HCC lesions17. Lesions <3cm received 48-75Gy in 3 fractions and those 3-
6cm received 36-60Gy in 6 fractions. Local control at one year was 86%. No patients 
with GTVs <5cm who received a biologically equivalent dose >100Gy (n=24) 
experienced local progression. Grade 3 liver enzyme elevation occurred in 7 patients 
(16%), accompanied by ascites in 5 CP B patients.  
 
Clinical evidence: Retrospective data  
Several retrospective series have been published. Those including more than 60 
patients are summarised in Table 2. The two largest studies are reviewed below.  
Sanuki et al in 2013 reported on 185 patients with 185 HCC lesions, all FP19. 
Patients were unsuitable for surgery or percutaneous ablative therapies. Planned 
prescription doses were 40Gy and 35Gy for patients with CP A and CP B disease 
respectively, in 5 fractions, reduced, as necessary, to meet constraints. Local control 
and overall survival at 3 years were 91% and 70% respectively, with no difference 
between 35Gy and 40Gy. Grade 3+ acute toxicities occurred in 13%. There were two 
episodes (1%) of grade 5 liver failure at 3 and 6 months, both in CP B patients. 
Patients who received 35Gy had more acute toxicities, likely reflecting the higher 
proportion of CP B disease (52%) in this group compared to the 40Gy group (1% CP 
B). CP score worsened by 2 points in 10%. 
 
Su et al reported on 114 CP A and 18 CP B patients unsuitable for surgery and 
percutaneous ablative therapies, with 175 HCC lesions, all FP20. Most patients 
(97%) received 42-46Gy in 3-5 fractions. Local control and overall survival at 1 year 
were 91% and 94% respectively. Grade 3+ toxicity developed in 8% (73% with CP B 
disease) including grade 3+ encephalopathy, grade 3-5 upper GI bleeding, grade 5 
hepatic failure and grade 5 hepatic haemorrhage. Multivariate analysis demonstrated 
that CP B disease was the only significant predictor of inferior survival. 
 
 
Summary: efficacy and safety of SBRT for HCC 
SBRT is effective in HCC, resulting in local control rates of 75-100% at 1 year, with 
responses achieved in the majority (Figure 1), and long-term survival reported21. Most 
patients have CP A disease, and between 1 and 3 lesions13,16,17,19,22-24, often 
measuring up to 5-7cm13,16,17,19,20,22-24. There is more limited experience of SBRT in 
patients with CP B disease. SBRT has frequently been employed in patients who 
have failed or are unsuitable for more established therapies. A wide range of dose-
fractionation schedules have been used, usually with lower doses in the presence of 
CP B disease.  
 
Grade 3+ toxicity has been reported in up to 30% and up to 38% of CP A and CP B 
patients respectively15,16. Hepatic and luminal toxicities are the most frequent 
toxicities. Deaths from liver failure are reported in up to 13% (most often in CP B 
patients) and high-grade luminal toxicities occur in up to 11% of patients13,14. Normal 
liver doses and the severity of cirrhosis are important in predicting hepatic 
toxicity15,16,25-27. Classic and non-classic radiation-induced liver disease (RILD) have 
been described28, both of which can progress to fulminant hepatic failure. Patients 
with underlying cirrhosis are also at increased risk of luminal toxicity14,15,20-22,29-31. 
 
Current questions: the place of SBRT for HCC 
Given the encouraging results in traditionally poor prognosis patients unsuitable for 
surgery or other local therapies, questions arise as to the role of SBRT as an 
alternative or adjunct to standard liver therapies. To date, no randomised evidence 
exists comparing SBRT to other HCC therapies, and selection bias hampers non-
randomised comparisons. Small retrospective studies have nonetheless attempted to 
address these questions and are discussed below.  
 
The addition of SBRT to TACE 
The combination of TACE and SBRT offers theoretical advantages: TACE may shrink 
tumours, creating a smaller target for SBRT, and the chemotherapy may provide 
radiosensitization; furthermore the lipiodal component is radio-opaque and may help 
with SBRT image guidance. Kang et al previously demonstrated encouraging results 
from SBRT following incomplete TACE14. Jacob et al and Honda et al, compared 
SBRT and TACE to TACE alone in tumours 3cm and cm respectively in 
retrospective series32,33. Both studies found that the addition of SBRT resulted in 
improved local control with no increase in high-grade toxicity. Furthermore, in 
tumours 3cm, after censoring for liver transplantation, overall survival was 
significantly better with TACE plus SBRT compared to TACE alone (median survival 
33 and 20 months respectively; p=0.02)32. There was no overall survival advantage 
from the combination in tumours FP, although disease free survival (DFS) was 
significantly better with the addition of SBRT in treatment naïve patients  (1-year DFS 
71.4% and 24.8% respectively, p=0.029)33. SBRT, therefore, based on this evidence, 
appears to complement TACE. 
 
Similar outcomes were observed by Paik et al who compared retrospective outcomes 
in 24 patients with a complete response to TACE (group 1) and 154 patients with an 
incomplete response to TACE who went on to receive: i) curative treatment (surgery, 
RFA, percutaneous ethanol injection; n=47; group 2), ii) SBRT (median 56Gy, range 
40-60Gy in 3-5 fractions; n=37; group 3) or iii) non-curative treatment (e.g. repeat 
TACE, sorafenib; n=70; group 4)34. Overall survival at 5 years was 50%, 58%, 53% 
and 28% in groups 1,2,3 and 4 respectively. There were no significant differences in 
survival between groups 1 to 3 while patients in group 4 fared significantly worse. 
Based on the above, therefore, following an incomplete response to TACE, SBRT 
appears competitive with curative therapies, and produces outcomes comparable to 
those achieved following a complete response to TACE. 
 
SBRT for portal vein thrombosis 
Patients with HCC portal vein thrombosis (PVT), a poor prognostic factor, have been 
included in several of the above studies13-18,21 where overall outcomes are better than 
expected. Recanalization of the vascular HCC following SBRT potentially facilitates 
TACE, which is less effective in the presence of main branch PVT. Where SBRT in 
HCC patients with PVT has been specifically examined, complete and partial 
responses have been reported in up to 37% and 75%, respectively, with 
recanalization in 44-76% and low rates (3.2%) of high-grade toxicity35-37.  The time 
to maximal response, however, may be many months (e.g. 6). 
 
SBRT as a bridge to transplant 
There is interest in the use of SBRT as a bridge to transplant in patients awaiting liver 
transplantation, since approximately 25% and 44% of patients drop off the waiting list 
due to HCC progression after 12 and 24 months respectively38. SBRT may help 
reduce this: following SBRT used as a bridging therapy, 63-100% of patients are 
reported to proceed to transplant, with low rates of toxicity, and with complete and 
partial pathological responses reported in 14-29% and 23-64% of lesions 
respectively39-43. Mohamed et al recently compared SBRT, TACE, RFA and yttrium-
90 microspheres as bridge to transplant therapies in a retrospective series of 60 
patients43. Mean pathological necrosis was not significantly different between 
modalities, and toxicities were lowest for SBRT and yttrium-90. Overall, despite small 
numbers and retrospective data, SBRT appears effective and well tolerated as a 
bridging therapy, and is competitive with other therapies.  
 
SBRT and sorafenib 
Pre-clinical data has suggested that the addition of sorafenib can enhance the tumour 
response to radiation44. Brade et al reported outcomes from a phase I trial of 
concurrent SBRT and sorafenib45. Overall there were 9, 2 and 1 episodes of grade 3, 
4 (liver enzyme changes and small bowel obstruction) and 5 (upper GI bleed/ HCC 
rupture) toxicities, at least possibly attributable to SBRT. It was therefore concluded 
that the concurrent use of sorafenib and SBRT in HCC is not recommended.  
 
Given the toxicities observed with concurrent therapy, sequential use of SBRT and 
sorafenib is being investigated in RTOG 1112, a phase III trial comparing SBRT 
followed by sorafenib with sorafenib alone in HCC patients unsuitable for standard 
local and regional therapies46.  Patients must have CP A GLVHDVH DQG  GLVFUHWH
tumour foci, with no one HCC >15cm and the maximum sum of HCC lesions <20cm. 
Main portal vein invasion and extra-hepatic disease up to a cumulative maximum of 
3cm are permissible. 
 
SBRT in comparison to other liver therapies 
In the setting of recurrent HCC, Huang et al compared retrospective outcomes 
between 36 patients (42 lesions) treated with a median of 37Gy (range 25-48) in 4-5 
daily fractions and 138 historical controls who received other liver therapies or no 
therapies47. On multivariate analysis, the absence of SBRT, tumour size >4cm, CP 
B/C and recurrent stage III/IV disease were predictors of inferior overall survival. 
There was one case of acute grade 3 gastric ulceration in the SBRT group, but no 
other high-grade acute toxicities. A matched-pair analysis of 28 SBRT patients and 
28 historical controls, found overall survival was better in the SBRT group (2-year 
survival 73% vs 42% in controls) as was time to progression (median 8.6 vs 3.5 
months). 
 
Shiowaza et al compared retrospective outcomes between SBRT and RFA, in 35 
patients treated with 3-5 fraction SBRT and 38 patients treated with RFA48. Patients 
who received SBRT were significantly older and had larger tumours. There were no 
significant differences in local control and overall survival. Late adverse events 
affected 4 patients in the SBRT group, including 2 deaths from hepatic failure, with no 
adverse events in the RFA group. SBRT therefore appeared competitive with RFA, 
albeit more toxic. 
 Wahl et al conducted a similar retrospective comparison between 63 patients (83 
tumours) treated with SBRT (median doses: 30Gy in 3 or 50Gy in 4 fractions) and 
161 patients (249 tumours) treated with RFA31. Patients who received SBRT had 
lower rates of cirrhosis, higher AFP levels and had received a greater number of 
previous liver therapies. Statistical methods were employed to adjust for imbalances. 
Freedom from local progression at 1 year was 97% and 84% for patients treated with 
SBRT and RFA respectively. For tumours <2cm, there was no difference in local 
control EHWZHHQ 5)$ DQG 6%57 )RU WXPRXUV FP 6%57 ZDV DVVRFLDWHG ZLWK
improved local control. On multivariate analysis, RFA, compared to SBRT, was 
associated with inferior local control. There was no significant difference in overall 
survival. There were 3 grade 3+ adverse events in the SBRT group (5%), and 18 in 
the RFA group (11%). The group concluded that there may be an advantage to SBRT 
in larger (FP+&&WXPRXUV 
 
Yuan et al compared outcomes in 48 patients with stage I HCC, 22 treated with SBRT 
(median 45Gy, range 39-54 in 3-8 fractions) and 26 who received microscopic 
complete resections49. Local control at 1 and 3 years after SBRT was 93% and 68% 
respectively. There was no significant difference in overall survival (3-year overall 
survival: 57% vs 69% for SBRT vs surgery) or progression free survival. 
 
These comparative studies suggest that SBRT is competitive with other, more 
established treatments. Given the potential for bias, however, randomised 
comparisons are warranted. 
 
 
 
SBRT technique 
Patient selection 
The most suitable HCC patients for SBRT have CP A disease. CP B patients have 
also been successfully treated although toxicity is more frequent, and lower doses 
should be considered for these patients. Preservation of adequate liver function and 
avoidance of excessive dose to luminal structures are needed: a threshold volume of 
uninvolved liver15-17,20 (often 700ml) may be specified, and a minimum distance (e.g. 
5mm) between tumours and luminal structures may be mandidated16,23,50. Much of the 
earlier evidence limited lesion size (often to <5-7cm) and number (often 3), and 
patients with vascular invasion or extra-hepatic disease have been excluded in some 
studies, but there is increasing successful use of SBRT in the setting of larger 
lesions, more numerous lesions and in the presence of adverse features15,18. 
 
Respiratory motion management 
Breath hold techniques using Activated Breathing Control devices 15,25,29 have been 
used to reduce respiratory motion51. Abdominal compression with 4D-CT have also 
been used to reduce respiratory motion19,21,50,52 as has respiratory gating29,32,41 and 
intra-fraction tracking of peri-tumoral implanted fiducials22,30,34,42,48 or external surface 
markers20,22,30,43,48 (which requires daily imaging to ensure the adopted breathing 
model remains satisfactory). Free breathing with 4D-CT, with individualised margins 
to account for respiration, have also been employed23.  
 
Simulation and contouring 
Intra-venous contrast-enhanced, multi-phasic CT is required for GTV delineation. 
Tumour enhances on the arterial phase before washing out during venous and 
delayed phases, obtained during breath hold.  4D-CT can aid in estimation of motion. 
MRI sequences can further assist with GTV definition. For SBRT, CTV margins are 
typically not employed14,16,19,20. PTV margins are usually individualised and are ideally 
5 mm but up to ~10mm may be required, depending on the motion management 
strategy.  
 
Planning  
A multi-beam approach, often including non-coplanar beams, is usually adopted to 
create highly conformal treatment plans13,15,16,20,29. Arc therapies have also been 
employed20,29. For the majority of HCC SBRT, dose has been prescribed to a 
peripheral isodose (typically 70-85%) covering the majority of the PTV, thus 
facilitating dose escalation within the PTV and rapid dose fall off beyond.  
 
Dose, fractionation and organ at risk constraints 
A variety of dose and fractionation schedules have been employed, most often using 
3 to 6 fractions. Both the severity of liver disease and normal tissue doses influence 
the chosen prescription dose. Some studies have found higher doses to be important 
for local control and overall survival13,21,30 but others have not14,15,18-20,23,29. Indeed, 
HCC appears to be a radiosensitive tumour, such that, above a certain threshold 
dose, there may be little benefit in further dose escalation, and potential for increased 
toxicity19.   
For small tumours away from luminal GI tissues, a fixed dose may be used (e.g. 
40Gy in 5 fractions), but for larger tumours, where doses must be limited because of 
normal liver tolerance, an individualised strategy, based on escalating dose based on 
liver constraints, is most appropriate. Varying approaches to dose selection have 
been adopted and include a biological individualised strategy based on the effective 
volume of irradiated liver and Lyman normal tissue complication probability (NTCP) 
estimation of classic RILD15,53, or a critical volume approach, which limits the dose 
received by a specified volume of normal liver14,17,21,23,25 (often 700ml). 
Uncertainties remain regarding the optimal HCC SBRT dose and liver constraints, 
and prospective data is required to define these further28. HCC SBRT dosimetry and 
dose-volume effects are discussed in greater detail elsewhere28,54. 
 
As well as liver doses, luminal doses are also important. One trial, with one of the 
highest high-grade GI toxicity rates, did not specify luminal constraints, which may 
have contributed to the high toxicity, although pre-existing GI ulceration may have 
had an impact14. Another study observed that all patients with high-grade GI toxicity 
had lesions <0.5cm from luminal structures21. Thus, luminal constraints, and/or 
specification of minimal distances between targets and lumen, are necessary.  
 
Image guidance 
Daily image guidance is necessary55. Orthogonal x-rays and cone beam CT (CBCT) 
are most commonly employed. CBCT matching has been suggested to be superior to 
orthogonal x-rays56. The use of peri-tumoral fiducials, with both x-rays and CBCT can 
further enhance set-up21,26,31,32,34,52,57. The presence of lipiodal following TACE, or 
surgical clips, have also been used as surrogates for tumour position21,26. Depending 
on the method of respiratory motion compensation, CBCT may be most usefully 
acquired in breath hold or as a 4D-CBCT to assist in matching.  
Future technical developments 
The use of intra-abdominal spacers to increase the distance between tumours and 
luminal structures can be used to reduce GI toxicity. These have been shown to 
displace the stomach and ERZHOE\2cm, with low complication rates58. The clinical 
implementation of deformable image registration has the potential to improve set-up 
accuracy in the face of organ deformation, which leads to discrepancies in planned 
versus delivered doses59. It may also have a role in CT and MRI co-registration prior 
to contouring, and in comparing pre- and post-treatment imaging59. The 
implementation of daily online image guidance using MRI in the context of the MR-
linac will provide enhanced soft tissue information compared to CBCT, thus improving 
set-up accuracy, without the need for fiducials. The system may also allow intra-
fraction motion monitoring. Adaptive radiotherapy would allow FUHDWLRQRIµSODQVRIWKH
GD\¶ EDVHG RQ HDFK GD\¶V anatomy, which could further improve accuracy. These 
measures may reduce uncertainties PTV margins, and normal tissue irradiation, 
hopefully reducing toxicities and improving the therapeutic ratio for HCC SBRT. 
 
Conclusions 
SBRT for HCC is effective in early phase trials and retrospective series, with 
acceptable toxicity, with long-term survival achieved in a proportion. Caution is 
required when treating patients with CP B disease. SBRT has been shown to 
complement existing HCC therapies, but comparative trials are required to better 
determine the place of SBRT amongst more recognised HCC treatments.  
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Table 1. Prospective studies of SBRT for HCC 
Study, year 
and 
type of data 
Median 
follow-up 
(months) 
No. 
patients 
No. 
lesions 
Child-Pugh 
class B** (%) 
PVT  
(%) 
Previous liver 
therapy (%) 
Median GTV 
diameter  
(cm, (range)) 
Dose (Gy)/  
no. fractions 
1-year 
Local 
control (%) 
1-year 
Overall 
survival (%) 
Grade 3+ 
toxicity (%) 
Mendez 
Romero 
200613 
Phase I/II 12.9 8 11 
 
 
25 25  
3.5 
(0.5-7.2) 
<4cm, no cirrhosis:  
37.5/3 η4cm or cirrhosis:  
25/5 or 30/3 75 
 
75 12.5 
Kang 
201214 
Phase II 
 
17 
 
47 
 
56 
 
13 
(all B7) 
 
11 
 
100 
 
2.9 
(1.3-7.8) 
 
42-60/3 
 
2-year: 95 
 
 
 
 
2-year: 69 
 
     
   11 (GI ulcer) 
9 (ascites) 
11 (thrombo-
cytopaenia) 
4 (hyper- 
bilirubinaemia) 
Bujold 
201315 
Phase I/II 31.4 102 
Multiple 
in 60.8%  0 55 52 
7.2 
(1.4-23.1) 
Median 36  
(range 24-54)/6 87 55 
 
 
 
 30 
 
Culleton 
201418 
Mixed on 
(n=14) and off 
study  
 
 
 
29 
 
Median 
of 2 
lesions 
97  
(B7/8/9: 
69/24/3) 
(CP10: 3) 
 
 
 
76 
 
 
 
14 
 
Sum of all 
lesions: 8.6 
(4.1-26.6) 
 
 
 
Median 30/6  
 
 
 
 
32  
Lasley 
201516 
Phase I/II 
CPA: 33 
CPB: 46 59 65 
36 
(B7/8+: 
81/19) 20 15 
Volume: 33.6ml 
(2.0-107.3) 
Median 48  
(range 36-48)/3 
CPB: 40/5* 
  CPA: 91 
CPB: 82 
CPA: 94 
CPB: 57 
CPA: 11 
CPB: 38 
Scorsetti 
201517 
Observational 
study 8 43 63 47 
 
 
20 
 
 
44 
4.8 cm  
(1.0-12.5) 
<3cm: 48-75/3 
3-6cm: 36-60/6 86 78 16 
*lower dose for CPB patients introduced after safety committee review, **percentage breakdown of CPB patients by CP score provided 
in parentheses if available, other patients mainly CPA or occasionally had no cirrhosis, unless otherwise stated, CP: Child Pugh, CR: 
complete response,                           
GI: gastrointestinal; HCC: hepatocellular carcinoma, PR: partial response, PVT: portal vein thrombosis, RECIST: Response Evaluation 
Criteria in Solid Tumours, SBRT: stereotactic body radiotherapy, SD: stable disease 
 
 
 
          Table 2. Retrospective studies of SBRT for HCC including >60 patients 
Study 
and year 
Median 
follow-up 
(months) 
No. 
patients 
No. 
lesions 
Child-Pugh 
class B** (%) 
PVT 
(%) 
Previous liver 
therapy (%) 
Median GTV 
diameter 
(cm, (range)) 
Dose (Gy) 
(range)/ 
fractions 
1- year 
Local 
control (%) 
1-year 
Overall 
survival (%) 
Grade 3+ 
toxicity (%) 
Bibault 
2013 30 10 75 96 
12 
(B7/8: 67/33)  
51% of 
lesions 
3.7 
(3.0-4.4) 45(24-45) /3 90 79 9.3% 
Jang 
201321* 30 82 95 
10 
(all CPB7) 10 100 
3.0 
(1.0-7.0) 
 
51(33-60)/3 2-year: 87 2-year: 63 
>54Gy: 
Bowel: 3.1% 
Other: 3.1% 
Sanuki 
201319 
35Gy: 31 
40Gy: 23 185 185 15  68 
35Gy: 
2.7 (1.0-5.0) 
40Gy: 
2.4 (0.8-5.0) 
CPA: 
40 (35-40)/5 
CPB: 
35 (35-40)/5 99 95 13% 
Yoon, Jung 
201323,26 26 93 
 
103 26  
 
99 
2.0 
(1.0-6.0) 
45/3  
(30-60/3-4), 95 86 
6.5% 
(hepatic) 
Takeda 
201450 31 63 63 16  68 
2.6 
(1.0-5.0) 
40 (35-40)/5 
CPB: 35/5 100         100 
21% at 6-12 
months 
Huestas 12 77 97 14  16 2.4 45(15-60)/3 99 82 Acute: 2.6% 
201522 (B7/8: 73/27) (0.7-6.3)  Late 6.5% 
Kimura 
201524 26 65 74 
14 
(B7/8: 56/44) 0 д92 
1.6 
(0.5-5.4) 48/4 100 92 
23.1% at 6-12 
months 
 
Yamashita 
201529 21 79 79 
11 
(CPC: 1%)  67 
2.7 
(0.6-7.0) 
48 
(40/4-60/10) 
At median 
FU: 82% 2-year: 53 
4.6%  
(all GI) 
Su 
201620 21 132 175 14  30 
3 
(1.1-5.0) 
42-46/3-5 
28-30/1 91 94 
8.3% 
(8/11 CPB) 
Wahl 
201631 13 63 83 
29 
(B7/8/9: 
38/46/17) 
(CPC: 2%)  
Median of 2 
prior 
therapies 
2.2 
(0-10.0) 
 
 
30/3 or  
50 /5 97 74 
5% at г30 
days, 
5.4% luminal , 
3.3% biliary 
at 1 year 
  * Retrospective series but includes patients reported in Kang et al prospective trial, **percentage breakdown of CPB patients by CP score 
provided in parentheses if available, other patients mainly CPA or occasionally no cirrhosis, unless otherwise stated, CP: Child Pugh, CR: 
complete response, FU: follow-up, GI: gastrointestinal; HCC: hepatocellular carcinoma, PR: partial response, PVT: portal vein thrombosis, 
RECIST: Response Evaluation Criteria in Solid Tumours, SBRT: stereotactic body radiotherapy, SD: stable disease 
 
 
Figure 1. Patient with HCC with venous invasion showing reduction in size and alpha-fetoprotein 
(AFP) in response to SBRT, 45Gy in 5 fractions: a) Pre-SBRT venous phase CT, b) SBRT plan 
(PTV for different respiratory phases shown in sold light green, cyan and pink) and c) 3-month 
post-SBRT venous phase CT 
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